Ovarian cancer is the 6th most common cancer among women, and the borderline category of ovarian tumors is poorly defined due to challenges in assessing stromal invasion.
A study evaluated the expression of hTERT, a potential biomarker, and serum CA-125 levels in 68 ovarian epithelial tumors to help differentiate between borderline tumors and malignancies.
Results showed high hTERT expression in cystadenocarcinomas and borderline tumors but the difference wasn't statistically significant, suggesting that a combination of hTERT immunohistochemistry and CA-125 could be useful in challenging diagnoses.